1Drop, a Boston, MA-based and Neuchatel, Switzerland-based life science company developing and commercializing a laboratory quality, portable medical diagnostic testing platform, closed a $4.25m Series A equity financing round.
The round – supported by VentureLab – was led by Christian Wildmoser (former partner CVC Capital Partners & Swiss Startup Group Investor) with particiation from Dr. Hans-Peter Strebel (owner of On Your Marks, the competence center for top athletics and research), Beat Schillig (IFJ Institute for Young Entrepreneurs) and Jean-Philippe de Toledo (CEO of Pharmacie Principale).
The company intends to use the funds to expand research and development and to commercialize its medical diagnostics platform.
Led by founder and CEO Dr. Luc Gervais, 1Drop enables personalized healthcare through non-invasive diagnostic tests providing actionable health information that is accessible to everyone at any time from a single drop of blood applied to a biochip.
Its diagnostic solutions for multiplexed assays of proteins, nucleic acids and peptides serve as tools for the development of new therapies, disease research, and clinical diagnostic tests.
The company is currently working with three pharmaceutical partners to create companion diagnostic products for cardiology, autoimmune disease and glucose metabolism drug candidates.
The company’s device has been thoroughly vetted in clinical validation studies in hospitals, clinical laboratories and pharmaceutical companies. 1Drop collaborates with Massachusetts General Hospital (MGH), Harvard University, the National Aeronautics and Space Administration (NASA), and the Swiss Federal Institute of Technology, Lausanne (EPFL).